



## Clinical trial results:

### A Phase III, Multi-Center, Multi-National, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of BMS-188667 in Children and Adolescents with Active Polyarticular Juvenile Rheumatoid Arthritis (JRA)

#### Summary

EudraCT number	2005-000443-28
Trial protocol	Outside EU/EEA
Global end of trial date	22 November 2011

#### Results information

Result version number	v1 (current)
This version publication date	05 January 2017
First version publication date	05 January 2017

#### Trial information

##### Trial identification

Sponsor protocol code	IM101-033
-----------------------	-----------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Bristol-Myers Squibb International Corporation
Sponsor organisation address	Chausse de la Hulpe 185, Brussels, Belgium, 1170
Public contact	Bristol-Myers Squibb Study Director, Bristol-Myers Squibb International Corporation, Clinical.Trials@bms.com
Scientific contact	Bristol-Myers Squibb Study Director, Bristol-Myers Squibb International Corporation, Clinical.Trials@bms.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-000118-PIP01-07
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	22 November 2011
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	22 November 2011
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary purpose of the clinical research study is to assess the safety of treating children and juvenile subjects with BMS-188667 (Abatacept). In addition, the study will assess the effectiveness of BMS-188667 in reducing disease activity of Juvenile Rheumatoid Arthritis (JRA) or Juvenile Idiopathic Arthritis (JIA) as measured by the time to occurrence of disease flare.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization Good Clinical Practice Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	05 February 2004
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Germany: 8
Country: Number of subjects enrolled	France: 28
Country: Number of subjects enrolled	United States: 31
Country: Number of subjects enrolled	Mexico: 41
Country: Number of subjects enrolled	Switzerland: 2
Country: Number of subjects enrolled	Peru: 19
Country: Number of subjects enrolled	Austria: 3
Country: Number of subjects enrolled	Spain: 8
Country: Number of subjects enrolled	Brazil: 48
Country: Number of subjects enrolled	Italy: 18
Country: Number of subjects enrolled	Portugal: 8
Worldwide total number of subjects	214
EEA total number of subjects	73

Notes:

### Subjects enrolled per age group

In utero	0
----------	---

Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	74
Adolescents (12-17 years)	140
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

The study was conducted in 45 sites in 11 countries.

### Pre-assignment

Screening details:

214 enrolled; in Per A, 190 treated; 24 not treated due to screening failures. 170 completed Per A, 123 responders qualified to enter Per B. One subject did not enter Per B; 122 responders were randomized, 60 abatacept and 62 placebo. 36 of 47 Per A non-responders re-entered at Per C. Protocol violation occurred; 5yr old participant.

### Period 1

Period 1 title	Open-Label Lead-In Phase (Period A)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

### Arms

<b>Arm title</b>	Abatacept (All Participants in Period A)
------------------	--

Arm description:

Abatacept: 10 milligram per kilogram body weight (mg/kg), limited to a maximum 1000 mg for participants weighing >100kg; solution infused intravenously (IV), over 90 minutes, once every 2 weeks for 3 doses.

Arm type	Experimental
Investigational medicinal product name	Abatacept
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Abatacept 10 milligram per kilogram body weight (mg/kg), limited to a maximum 1000 mg for participants weighing >100kg; solution infused intravenously (IV), over 90 minutes, once every 2 weeks for 3 doses.

<b>Number of subjects in period 1<sup>[1]</sup></b>	Abatacept (All Participants in Period A)
Started	190
Completed	170
Not completed	20
Consent withdrawn by subject	1
Adverse event, non-fatal	1
Not Specified	1
Lack of efficacy	17

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: 214 were enrolled but only were 190 treated; 24 not treated due to screening failures

## Period 2

Period 2 title	Double-Blind Phase (Period B)
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

## Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Abatacept (Period B)

Arm description:

Abatacept: 10 milligram per kilogram body weight (mg/kg), limited to a maximum 1000 mg for participants weighing >100kg; solution infused intravenously (IV), over 90 minutes, once a month for 6 months or until they experienced a flare (Period B).

Arm type	Experimental
Investigational medicinal product name	Abatacept
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Abatacept 10 milligram per kilogram body weight (mg/kg), limited to a maximum 1000 mg for participants weighing >100kg; solution infused intravenously (IV), over 90 minutes, once a month for 6 months or until they experienced a flare.

<b>Arm title</b>	Placebo (Period B)
------------------	--------------------

Arm description:

Placebo: Dextrose 5% in water (D5W) or normal saline (NS) IV infusion, once every 2 weeks for 3 doses, then monthly up to 6 months. Participants were seated or in supine position during infusion.

Arm type	Placebo
Investigational medicinal product name	Dextrose 5% in water
Investigational medicinal product code	
Other name	D5W
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Dextrose 5% in water (D5W) IV infusion, once every 2 weeks for 3 doses, then monthly up to 6 months. Participants were seated or in supine position during infusion.

Investigational medicinal product name	Saline
Investigational medicinal product code	
Other name	NS
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Normal saline (NS) IV infusion, once every 2 weeks for 3 doses, then monthly up to 6 months. Participants were seated or in supine position during infusion.

<b>Number of subjects in period 2<sup>[2]</sup></b>	Abatacept (Period B)	Placebo (Period B)
Started	60	62
Completed	49	31
Not completed	11	31
Consent withdrawn by subject	1	-
Lack of efficacy	10	31

Notes:

[2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: 170 subjects completed Period A. Of those, 123 were responders who qualified to enter Period B. 122 subjects were randomized, 60 to Abatacept and 62 to placebo. One chose not to enter Period B.

### Period 3

Period 3 title	Open-Label Extension Phase (Period C)
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Abatacept (Period C)

Arm description:

Abatacept: 10 milligram per kilogram body weight (mg/kg), limited to a maximum 1000 mg for participants weighing >100kg; solution infused intravenously (IV), over 90 minutes, once a month for up to 5 years.

Arm type	Experimental
Investigational medicinal product name	Abatacept
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Abatacept 10 milligram per kilogram body weight (mg/kg), limited to a maximum 1000 mg for participants weighing >100kg; solution infused intravenously (IV), over 90 minutes, once a month for up to 5 years.

<b>Arm title</b>	Placebo (Period B) to Abatacept (Period C)
------------------	--

Arm description:

Participants from Period B Placebo group entering Period C. Abatacept: 10 milligram per kilogram body weight (mg/kg), limited to a maximum 1000 mg for participants weighing >100kg; solution infused intravenously (IV), over 90 minutes, once a month for up to 5 years.

Arm type	Experimental
Investigational medicinal product name	Abatacept
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Abatacept 10 milligram per kilogram body weight (mg/kg), limited to a maximum 1000 mg for participants weighing >100kg; solution infused intravenously (IV), over 90 minutes, once a month for up to 5 years.

<b>Number of subjects in period 3</b>	<b>Abatacept (Period C)</b>	<b>Placebo (Period B) to Abatacept (Period C)</b>
Started	47	33
Completed	29	27
Not completed	29	32
No Longer Meets Study Criteria	1	1
Adverse event, serious fatal	-	1
Consent withdrawn by subject	6	-
Poor/Non-Compliance	2	2
Adverse event, non-fatal	2	3
Pregnancy	2	3
Not Specified	6	8
Lost to follow-up	5	6
Lack of efficacy	5	8
Joined	11	26
Subjects who discontinued Per B rejoining at Per C	11	26

## Baseline characteristics

### Reporting groups

Reporting group title	Abatacept (All Participants in Period A)
Reporting group description: Abatacept: 10 milligram per kilogram body weight (mg/kg), limited to a maximum 1000 mg for participants weighing >100kg; solution infused intravenously (IV), over 90 minutes, once every 2 weeks for 3 doses.	

Reporting group values	Abatacept (All Participants in Period A)	Total	
Number of subjects	190	190	
Age categorical Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	63	63	
Adolescents (12-17 years)	127	127	
Adults (18-64 years)	0	0	
From 65-84 years	0	0	
85 years and over	0	0	
Age Continuous Units: years			
median	13		
full range (min-max)	5 to 17	-	
Gender, Male/Female Units: participants			
Female	137	137	
Male	53	53	

### Subject analysis sets

Subject analysis set title	Abatacept (All participants in Period A)
Subject analysis set type	Full analysis
Subject analysis set description: Abatacept: 10 milligram per kilogram body weight (mg/kg), limited to a maximum 1000 mg for participants weighing >100kg; solution infused intravenously (IV), over 90 minutes, once every 2 weeks for 3 doses.	
Subject analysis set title	Abatacept (All Participants in Period C)
Subject analysis set type	Sub-group analysis
Subject analysis set description: All participants in Period C; composite of those who completed Period B plus those non-responders from Period A who re-entered at Period C.	
Subject analysis set title	Placebo (Period B) to Abatacept (Period C)
Subject analysis set type	Sub-group analysis
Subject analysis set description: Participants from Period B Placebo group entering Period C. Abatacept: 10 milligram per kilogram body	



weight (mg/kg), limited to a maximum 1000 mg for participants weighing >100kg; solution infused intravenously (IV), over 90 minutes, once a month for up to 5 years.

Subject analysis set title	Abatacept (Period A Non-Responders in Period C)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants not eligible to continue into Period B but re-entered in Period C. Abatacept: 10 milligram per kilogram body weight (mg/kg), limited to a maximum 1000 mg for participants weighing >100kg; solution infused intravenously (IV), over 90 minutes, once every two weeks for three doses (Period A) and once a month for up to 5 years (Period C).

Reporting group values	Abatacept (All participants in Period A)	Abatacept (All Participants in Period C)	Placebo (Period B) to Abatacept (Period C)
Number of subjects	190	153	59
Age categorical Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	63		
Adolescents (12-17 years)	127		
Adults (18-64 years)	0		
From 65-84 years	0		
85 years and over	0		
Age Continuous Units: years			
median	13		
full range (min-max)	5 to 17		
Gender, Male/Female Units: participants			
Female	137		
Male	53		

Reporting group values	Abatacept (Period A Non-Responders in Period C)		
Number of subjects	36		
Age categorical Units: Subjects			
In utero			
Preterm newborn infants (gestational age < 37 wks)			
Newborns (0-27 days)			
Infants and toddlers (28 days-23 months)			
Children (2-11 years)			
Adolescents (12-17 years)			
Adults (18-64 years)			
From 65-84 years			
85 years and over			

Age Continuous Units: years median full range (min-max)			
Gender, Male/Female Units: participants			
Female Male			

---

## End points

### End points reporting groups

Reporting group title	Abatacept (All Participants in Period A)
Reporting group description: Abatacept: 10 milligram per kilogram body weight (mg/kg), limited to a maximum 1000 mg for participants weighing >100kg; solution infused intravenously (IV), over 90 minutes, once every 2 weeks for 3 doses.	
Reporting group title	Abatacept (Period B)
Reporting group description: Abatacept: 10 milligram per kilogram body weight (mg/kg), limited to a maximum 1000 mg for participants weighing >100kg; solution infused intravenously (IV), over 90 minutes, once a month for 6 months or until they experienced a flare (Period B).	
Reporting group title	Placebo (Period B)
Reporting group description: Placebo: Dextrose 5% in water (D5W) or normal saline (NS) IV infusion, once every 2 weeks for 3 doses, then monthly up to 6 months. Participants were seated or in supine position during infusion.	
Reporting group title	Abatacept (Period C)
Reporting group description: Abatacept: 10 milligram per kilogram body weight (mg/kg), limited to a maximum 1000 mg for participants weighing >100kg; solution infused intravenously (IV), over 90 minutes, once a month for up to 5 years.	
Reporting group title	Placebo (Period B) to Abatacept (Period C)
Reporting group description: Participants from Period B Placebo group entering Period C. Abatacept: 10 milligram per kilogram body weight (mg/kg), limited to a maximum 1000 mg for participants weighing >100kg; solution infused intravenously (IV), over 90 minutes, once a month for up to 5 years.	
Subject analysis set title	Abatacept (All participants in Period A)
Subject analysis set type	Full analysis
Subject analysis set description: Abatacept: 10 milligram per kilogram body weight (mg/kg), limited to a maximum 1000 mg for participants weighing >100kg; solution infused intravenously (IV), over 90 minutes, once every 2 weeks for 3 doses.	
Subject analysis set title	Abatacept (All Participants in Period C)
Subject analysis set type	Sub-group analysis
Subject analysis set description: All participants in Period C; composite of those who completed Period B plus those non-responders from Period A who re-entered at Period C.	
Subject analysis set title	Placebo (Period B) to Abatacept (Period C)
Subject analysis set type	Sub-group analysis
Subject analysis set description: Participants from Period B Placebo group entering Period C. Abatacept: 10 milligram per kilogram body weight (mg/kg), limited to a maximum 1000 mg for participants weighing >100kg; solution infused intravenously (IV), over 90 minutes, once a month for up to 5 years.	
Subject analysis set title	Abatacept (Period A Non-Responders in Period C)
Subject analysis set type	Sub-group analysis
Subject analysis set description: Participants not eligible to continue into Period B but re-entered in Period C. Abatacept: 10 milligram per kilogram body weight (mg/kg), limited to a maximum 1000 mg for participants weighing >100kg; solution infused intravenously (IV), over 90 minutes, once every two weeks for three doses (Period A) and once a month for up to 5 years (Period C).	

**Primary: Median Time to Occurrence of Juvenile Rheumatoid Arthritis/Juvenile Idiopathic Arthritis (JRA/JIA) Disease Flare During Double-Blind Phase (Period B)**

End point title	Median Time to Occurrence of Juvenile Rheumatoid Arthritis/Juvenile Idiopathic Arthritis (JRA/JIA) Disease Flare During Double-Blind Phase (Period B)
-----------------	---

## End point description:

Time to flare is defined as the elapsed number of days between the first dose date in Period B and the study day that disease flare is confirmed.

All of the following criteria must be met to be defined as a flare:

- > 30% worsening in at least 3 of the 6 JRA/JIA core response variables
- > 30% improvement in not more than 1 of the 6 JRA/JIA core set variables
- $\geq 2$  cm of worsening must be present if the Physician or Parent Global Assessment is used to define flare
- worsening in  $\geq 2$  joints must be present if the number of active joints or joints with limitation of motion is used to define flare based on changes in the surrogate marker, erythrocyte sedimentation rate (ESR)

The analysis population included all treated subjects.

Here, 99999 signifies that the value was not estimated. Fewer than 50% of the participants in the abatacept group experienced a flare, therefore the median time to flare is known to exceed 6 months, but cannot be estimated.

End point type	Primary
End point timeframe:	
Period B (Day 113 to Day 282)	

End point values	Abatacept (Period B)	Placebo (Period B)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	60	62		
Units: months				
number (not applicable)	99999	6		

**Statistical analyses**

<b>Statistical analysis title</b>	Comparison of Abatacept to Placebo
Comparison groups	Abatacept (Period B) v Placebo (Period B)
Number of subjects included in analysis	122
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0002
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.31
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.16
upper limit	0.59

---

**Secondary: Number of Participants with a Juvenile Rheumatoid Arthritis/Juvenile Idiopathic Arthritis (JRA/JIA) Disease with a Flare During Double-Blind Phase (Period B)**

---

End point title	Number of Participants with a Juvenile Rheumatoid Arthritis/Juvenile Idiopathic Arthritis (JRA/JIA) Disease with a Flare During Double-Blind Phase (Period B)
-----------------	---

End point description:

All of the following criteria must be met to be defined as a flare:

- > 30% worsening in at least 3 of the 6 JRA/JIA core response variables
- > 30% improvement in not more than 1 of the 6 JRA/JIA core set variables
- ≥ 2 cm of worsening must be present if the Physician or Parent Global Assessment is used to define flare
- worsening in ≥ 2 joints must be present if the number of active joints or joints with limitation of motion is used to define flare based on changes in the surrogate marker, erythrocyte sedimentation rate (ESR)

The analysis population included all treated subjects.

End point type	Secondary
----------------	-----------

End point timeframe:

Period B (Day 113 to Day 282)

---

End point values	Abatacept (Period B)	Placebo (Period B)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	60	62		
Units: participants				
number (not applicable)	12	33		

**Statistical analyses**

Statistical analysis title	Comparison of Abatacept to Placebo
Comparison groups	Abatacept (Period B) v Placebo (Period B)
Number of subjects included in analysis	122
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Chi-squared

---

**Secondary: Number of Participants With Serious Adverse Events (SAEs), Treatment-Related AEs, Deaths, Discontinuation of Study Drug Due to AEs During Open-Label Lead-In Phase (Period A)**

---

End point title	Number of Participants With Serious Adverse Events (SAEs), Treatment-Related AEs, Deaths, Discontinuation of Study Drug Due to AEs During Open-Label Lead-In Phase (Period A)
-----------------	---

---

**End point description:**

AE=any new unfavorable symptom, sign or disease or worsening of a preexisting condition that may not have a causal relationship with treatment.

SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity or drug dependency/abuse; is life-threatening, an important medical event or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible or missing relationship to study drug. Death=during the study and up to 28 days past study discontinuation. The select AEs were determined using the Medical Dictionary for Regulatory Activities (MedDRA, v14.1).

The analysis population included all treated subjects in Period A.

---

End point type	Secondary
----------------	-----------

---

End point timeframe:

Period A (Day 1 to Day 113)

---

<b>End point values</b>	Abatacept (All Participants in Period A)			
Subject group type	Reporting group			
Number of subjects analysed	190			
Units: participants				
number (not applicable)				
SAE	6			
Treatment-Related AE	0			
All Deaths	0			
Treatment-Related Deaths	0			
Discontinuation of Study Drug due to AEs	1			

---

**Statistical analyses**

No statistical analyses for this end point

---

---

**Secondary: Number of Participants With Serious Adverse Events (SAEs), Treatment-Related AEs, Deaths, Discontinuation of Study Drug Due to AEs During Double-Blind Phase (Period B)**

---

---

End point title	Number of Participants With Serious Adverse Events (SAEs), Treatment-Related AEs, Deaths, Discontinuation of Study Drug Due to AEs During Double-Blind Phase (Period B)
-----------------	---

---

**End point description:**

AE=any new unfavorable symptom, sign or disease or worsening of a preexisting condition that may not have a causal relationship with treatment.

SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity or drug dependency/abuse; is life-threatening, an important medical event or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible or missing relationship to study drug. Death=during the study and up to 28 days past study discontinuation. The select AEs were determined using the Medical Dictionary for Regulatory Activities (MedDRA, v14.1).

The analysis population included all treated subjects during Period B.

---

End point type	Secondary
----------------	-----------

---

End point timeframe:

Period B (Day 113 to Day 282)

---

<b>End point values</b>	Abatacept (Period B)	Placebo (Period B)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	60	62		
Units: participants				
number (not applicable)				
SAE	0	2		
Treatment-Related AE	0	0		
All Deaths	0	0		
Treatment-Related Deaths	0	0		
Discontinuation of Study Drug due to AEs	0	0		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Participants With Serious Adverse Events (SAEs), Treatment-Related AEs, Deaths, Discontinuation of Study Drug Due to AEs During Open-Label Phase (Period C)

End point title	Number of Participants With Serious Adverse Events (SAEs), Treatment-Related AEs, Deaths, Discontinuation of Study Drug Due to AEs During Open-Label Phase (Period C)
-----------------	---

End point description:

AE=any new unfavorable symptom, sign or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity or drug dependency/abuse; is life-threatening, an important medical event or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible or missing relationship to study drug. Death=during the study and up to 85 days past study discontinuation. The select AEs were determined using the Medical Dictionary for Regulatory Activities (MedDRA, v14.1).

The analysis population included all treated subjects in Period C.

End point type	Secondary
----------------	-----------

End point timeframe:

Period C (Day 282 to end of study)

<b>End point values</b>	Abatacept (Period C)	Placebo (Period B) to Abatacept (Period C)	Abatacept (Period A Non- Responders in Period C)	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	58	59	36	
Units: participants				
number (not applicable)				
SAE	9	12	9	
Treatment-Related AE	4	3	2	

All Deaths	0	1	0	
Treatment-Related Deaths	0	0	0	
Discontinuation of Study Drug due to AEs	2	3	1	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Median Percent Change From Baseline in JRA/JIA Core Set Variables During Double-Blind Phase (Period B)

End point title	Median Percent Change From Baseline in JRA/JIA Core Set Variables During Double-Blind Phase (Period B)
-----------------	--

End point description:

Percent change from baseline was calculated from the difference between post-baseline and baseline divided by baseline multiplied by 100 and reported as the range between 25th and 75th percentile, not full range; American College of Rheumatology (ACR) Pediatric 30 JRA/JIA core set variables include active joints, limited range of motion, physician's global assessment of disease severity, parent global assessment of overall well-being, change in physical function as measured by the Childhood Health Assessment Questionnaire (CHAQ), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).

The analysis population included all treated subjects in Period B.

End point type	Secondary
----------------	-----------

End point timeframe:

Period B (Day 113 to Day 282)

End point values	Abatacept (Period B)	Placebo (Period B)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	60	62		
Units: percentage change from baseline				
median (inter-quartile range (Q1-Q3))				
Active Joints	-20.9 (-92 to 17.86)	50 (0 to 100)		
Joints with LOM	0 (-45.5 to 0)	50 (0 to 100)		
Physical Global Assessment	-29.8 (-86.3 to 22.48)	55.95 (-31.3 to 250)		
Parent Global Assessment	-11.2 (-56.8 to 28.41)	8.39 (-31.8 to 100)		
CHAQ Disability Index	0 (-38.9 to 2.17)	0 (-13.3 to 55.56)		
ESR	0 (-20.7 to 50)	20.5 (-14.3 to 92)		
CRP	0 (-46.6 to 67)	6.25 (-33.3 to 150)		

## Statistical analyses



No statistical analyses for this end point

### Secondary: Median Percent Change From Baseline in JRA/JIA Core Set Variables During Open-Label Phase (Period C)

End point title	Median Percent Change From Baseline in JRA/JIA Core Set Variables During Open-Label Phase (Period C)
-----------------	--

End point description:

Percent change from baseline was calculated from the difference between post-baseline and baseline divided by baseline multiplied by 100 and reported as the range between 25th and 75th percentile, not full range; American College of Rheumatology (ACR) Pediatric 30 JRA/JIA core set variables include active joints, limited range of motion, physician's global assessment of disease severity, parent global assessment of overall well-being, change in physical function as measured by the Childhood Health Assessment Questionnaire (CHAQ), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).

All treated subjects in Period C

End point type	Secondary
----------------	-----------

End point timeframe:

Period C (Day 282 to end of study)

End point values	Abatacept (Period C)	Placebo (Period B) to Abatacept (Period C)	Abatacept (Period A Non-Responders in Period C)	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	58	59	36	
Units: percentage change from baseline median (inter-quartile range (Q1-Q3))				
Active Joints	-70.2 (-94.1 to -50)	-82.4 (-100 to -62.5)	-26.7 (-66.7 to 0)	
Joints with Limited Range of Motion	-50 (-75 to -27.3)	-71.4 (-86.2 to -23.1)	0 (-33.3 to 36.67)	
Physician's Global Assessment of Disease Severity	-75 (-91.3 to -52.3)	-81.8 (-91.4 to -64.3)	-31.9 (-50 to -9.33)	
Parent Global Assessment of Overall Well-Being	-62.7 (-93.8 to -27.5)	-63.9 (-84.2 to -38.8)	1.96 (-19.6 to 26.67)	
CHAQ Disability Index	-56.7 (-81.8 to -18.2)	-45.5 (-75 to -12.5)	14.14 (-16.7 to 100)	
ESR	-27.3 (-54.8 to 20)	-24.2 (-50 to 0)	20.87 (-15.5 to 83.77)	
CRP	-33.8 (-84.4 to 54.84)	-27.8 (-75 to 11.11)	0 (-31.6 to 43.68)	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Events of Special Interest During Open-Label Lead-In Phase (Period A), Including Infections, Peri-Infusional Adverse Events (AEs), Autoimmune Disorders and Malignancies

End point title	Events of Special Interest During Open-Label Lead-In Phase (Period A), Including Infections, Peri-Infusional Adverse Events (AEs), Autoimmune Disorders and Malignancies
-----------------	--

End point description:

The sponsor prospectively identified categories of AEs that may be associated with the use of immunomodulatory drugs including infections, peri-infusional AEs, autoimmune disorders, malignancies. Peri-infusional AEs are defined as those AEs of special interest occurring during the first 24 hours after the start of study drug infusion. Malignancies definitions were based on events in the MedDRA Maintenance and Support Services Organization (MSSO) malignancies Structured MedDRA Query (SMQ). Autoimmune disorders are in alignment with the pre-specified MedDRA codes of autoimmune disorders events of interest.

The analysis population included all treated subjects in Period A.

End point type	Secondary
----------------	-----------

End point timeframe:

Period A (Day 1 to Day 113)

End point values	Abatacept (All Participants in Period A)			
Subject group type	Reporting group			
Number of subjects analysed	190			
Units: participants				
number (not applicable)				
Infections and Infestations	68			
Peri-Infusional AEs	30			
Autoimmune Disorders	2			
Malignancies	0			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Events of Special Interest During Double-Blind Phase (Period B), Including Infections, Peri-Infusional Adverse Events (AEs), Autoimmune Disorders and Malignancies

End point title	Events of Special Interest During Double-Blind Phase (Period B), Including Infections, Peri-Infusional Adverse Events (AEs), Autoimmune Disorders and Malignancies
-----------------	--

End point description:

The sponsor prospectively identified categories of AEs that may be associated with the use of immunomodulatory drugs including infections, peri-infusional AEs, autoimmune disorders, malignancies. Peri-infusional AEs are defined as those AEs of special interest occurring during the first 24 hours after the start of study drug infusion. Malignancies definitions were based on events in the MedDRA Maintenance and Support Services Organization (MSSO) malignancies Structured MedDRA Query (SMQ). Autoimmune disorders are in alignment with the pre-specified MedDRA codes of autoimmune disorders events of interest.

The analysis population included all treated subjects in Period B.

End point type	Secondary
----------------	-----------

End point timeframe:

Period B (Day 113 to Day 282)

<b>End point values</b>	Abatacept (Period B)	Placebo (Period B)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	60	62		
Units: participants				
number (not applicable)				
Infections and Infestations	27	27		
Peri-Infusional AEs	2	2		
Autoimmune Disorders	0	0		
Malignancies	0	0		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Events of Special Interest During Open-Label Phase (Period C), Including Infections, Peri-Infusional Adverse Events (AEs), Autoimmune Disorders and Malignancies

End point title	Events of Special Interest During Open-Label Phase (Period C), Including Infections, Peri-Infusional Adverse Events (AEs), Autoimmune Disorders and Malignancies
-----------------	--

End point description:

The sponsor prospectively identified categories of AEs that may be associated with the use of immunomodulatory drugs including infections, peri-infusional AEs, autoimmune disorders, malignancies. Peri-infusional AEs are defined as those AEs of special interest occurring during the first 24 hours after the start of study drug infusion. Malignancies definitions were based on events in the MedDRA Maintenance and Support Services Organization (MSSO) malignancies Structured MedDRA Query (SMQ). Autoimmune disorders are in alignment with the pre-specified MedDRA codes of autoimmune disorders events of interest.

The analysis population included all treated subjects in Period C.

End point type	Secondary
----------------	-----------

End point timeframe:

Period C (Day 282 up to 56 days after the last dose of study medication)

<b>End point values</b>	Abatacept (All Participants in Period C)			
Subject group type	Subject analysis set			
Number of subjects analysed	153			
Units: participants				
number (not applicable)				
Infections and Infestations	120			
Peri-Infusional AEs	22			
Autoimmune Disorders	7			
Malignancies	1			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Participants Achieving American College of Rheumatology (ACR) Pediatric 30 (ACRP30), ACR Pediatric 50, ACR Pediatric 70, ACR Pediatric 90, and Inactive Disease Status Erythrocyte Sedimentation Rate (ESR) Response Rate

End point title	Percentage of Participants Achieving American College of Rheumatology (ACR) Pediatric 30 (ACRP30), ACR Pediatric 50, ACR Pediatric 70, ACR Pediatric 90, and Inactive Disease Status Erythrocyte Sedimentation Rate (ESR) Response Rate
-----------------	---

End point description:

The ACRP30 response criteria were defined as a  $\geq 30\%$  improvement over baseline in ESR. ACRP 50, 70, and 90 responses were defined similarly with 50%, 70%, and 90% improvements required, respectively.

Here '99999' signifies not estimable data and -99999 to 99999 signifies that no confidence interval is applicable.

The analysis population included all treated subjects.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 113, Day 282, and Day 2047

End point values	Abatacept (Period C)	Placebo (Period B) to Abatacept (Period C)	Abatacept (Period A Non-Responders in Period C)	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	58	59	36	
Units: percentage of participants				
number (confidence interval 95%)				
ACR Pediatric 30 (ESR) at Day 113	100 (-99999 to 99999)	100 (-99999 to 99999)	0 (-99999 to 99999)	
ACR Pediatric 30 (ESR) at Day 282	84.5 (75.2 to 93.8)	67.8 (55.9 to 79.7)	99999 (-99999 to 99999)	
ACR Pediatric 30 (ESR) at Day 2047	97 (91.1 to 100)	86.7 (74.5 to 98.8)	69.2 (44.1 to 94.3)	
ACR Pediatric 50 (ESR) at Day 113	65.5 (53.3 to 77)	88.1 (79.9 to 96.4)	0 (-99999 to 99999)	
ACR Pediatric 50 (ESR) at Day 282	79.3 (68.9 to 89.7)	52.5 (39.8 to 65.3)	99999 (-99999 to 99999)	
ACR Pediatric 50 (ESR) at Day 2047	93.9 (85.8 to 100)	80 (65.7 to 94.3)	69.2 (44.1 to 94.3)	
ACR Pediatric 70 (ESR) at Day 113	37.9 (25.4 to 50.4)	49.2 (36.4 to 61.9)	0 (-99999 to 99999)	
ACR Pediatric 70 (ESR) at Day 282	55.2 (42.4 to 68)	30.5 (18.8 to 42.3)	99999 (-99999 to 99999)	
ACR Pediatric 70 (ESR) at Day 2047	78.8 (64.89 to 92.7)	63.3 (46.1 to 80.6)	53.8 (26.7 to 80.9)	

ACR Pediatric 90 (ESR) at Day 113	17.2 (7.5 to 27)	22 (11.5 to 32.6)	0 (-99999 to 99999)	
ACR Pediatric 90 (ESR) at Day 282	41.4 (28.7 to 54.1)	15.3 (6.1 to 24.4)	99999 (-99999 to 99999)	
ACR Pediatric 90 (ESR) at Day 2047	66.7 (50.6 to 82.8)	40 (22.5 to 57.5)	38.5 (12 to 64.9)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Treated Participants with Marked Laboratory Abnormalities During Open-Label Lead-In Phase (Period A)

End point title	Number of Treated Participants with Marked Laboratory Abnormalities During Open-Label Lead-In Phase (Period A)
-----------------	--

End point description:

Marked abnormalities were pre-defined as changes after drug infusion reported relative to normal. Hemoglobin, 11.6-14.8 grams per deciliter (g/dL); Hematocrit, 36.0-50.0%; Erythrocytes, 3.80-5.10x10<sup>6</sup> cells per microliter (c/uL); Platelets, 140-44 cells per liter (c/L); Leukocytes, 4.00-12.50 c/uL; Absolute Neutrophils + Bands, if <1.00x10<sup>3</sup> c/uL; Absolute Lymphocytes, if <0.72x10<sup>3</sup> or >7.50x10<sup>3</sup> c/uL; Absolute Eosinophils, if >0.750x10<sup>3</sup> c/uL; Alanine Aminotransferase, 0-40 units per liter (U/L); G-Glutamyl Transferase, 0-60 U/L; Bilirubin, 0.1-1.2 milligrams per deciliter (mg/dL); Blood Urea Nitrogen, 5.9-26.0 mg/dL; Creatinine, 0.50-1.50 mg/dL; Serum Potassium, 3.5-5.5 milliequivalents per liter (mEq/L); Serum Glucose, 65-99 mg/dL; Fasting Serum Glucose, 65-99 mg/dL; Total Protein, 6.0-8.5 g/dL; Albumin, 3.5-5.5 g/dL; Urine Protein, >=4; Urine Glucose, >=4; Urine Blood, >=4; Urine Red Blood Cells >=4; Urine White Blood Cells, >=4. The analysis population included all treated and evaluated subjects in Per A.

End point type	Secondary
----------------	-----------

End point timeframe:

Period A (Day 1 to Day 113)

End point values	Abatacept (All Participants in Period A)	Abatacept (All participants in Period A)		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	190	190		
Units: participants				
number (not applicable)				
Hemoglobin (Low) n=189	2	2		
Hematocrit (Low) n=189	2	2		
Erythrocytes (Low) n=189	1	1		
Platelets (Low) n=189	1	1		
Platelet Count (High) n=189	2	2		
Leukocytes (Low) n=189	9	9		
Leukocytes (High) n=189	10	10		
Absolute Neutrophils + Bands (Low) n=189	5	5		
Absolute Lymphocytes (Low) n=189	9	9		
Absolute Eosinophils (High) n=189	16	16		
Alanine Aminotransferase (ALT, High) n=190	2	2		

G-Glutamyl Transferase (GGT, High) n=190	1	1		
Bilirubin (Total, High) n=190	1	1		
Blood Urea Nitrogen (High) n=190	6	6		
Creatinine (High) n=190	12	12		
Potassium (High) n=190	4	4		
Serum Glucose (Low) n=190	26	26		
Serum Glucose (High) n=190	2	2		
Fasting Serum Glucose (High) n=109	1	1		
Total Protein (High) n=190	2	2		
Albumin (Low) n=190	2	2		
Urine Protein (High) n=190	12	12		
Urine Glucose (High) n=190	1	1		
Urine Blood (High) n=190	23	23		
Urine White Blood Cells (High) n=75	9	9		
Urine Red Blood Cells (High) n=75	25	25		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Treated Participants with Marked Laboratory Abnormalities During Double-Blind Phase (Period B)

End point title	Number of Treated Participants with Marked Laboratory Abnormalities During Double-Blind Phase (Period B)
-----------------	--

End point description:

Marked abnormalities were pre-defined as changes occurring after drug infusion and reported relative to normal. Hemoglobin, 11.6-14.8 grams per deciliter (g/dL); Hematocrit, 36.0-50.0 percent; Erythrocytes, 3.80-5.10x10<sup>6</sup> cells per microliter (c/uL); Platelets, 140-44 cells per liter (c/L); Leukocytes, 4.00-12.50 c/uL; Absolute Neutrophils + Bands, if <1.00x10<sup>3</sup> c/uL; Absolute Lymphocytes, if <0.72x10<sup>3</sup> or >7.50x10<sup>3</sup> c/uL; Absolute Eosinophils, if >0.750x10<sup>3</sup> c/uL; Aspartate Aminotransferase, 0-40 units per liter (U/L); Alanine Aminotransferase, 0-40 U/L; Blood Urea Nitrogen, 5.9-26.0 mg/dL; Serum Sodium, 135-148 milliequivalents per liter (mEq/L); Serum Potassium, 3.5-5.5 mEq/L; Serum Glucose, 65-99 mg/dL; Fasting Serum Glucose, 65-99 mg/dL; Urine Protein, >=4; Urine Blood, >=4; Urine Red Blood Cells >=4; Urine White Blood Cells, >=4. The analysis population included all treated and evaluated subjects in Period B.

End point type	Secondary
----------------	-----------

End point timeframe:

Period B (Day 113 to Day 282)

End point values	Abatacept (Period B)	Placebo (Period B)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	60	62		
Units: participants				
number (not applicable)				
Hemoglobin (Low) n=60, 61	1	1		
Hematocrit (Low) n=60, 61	1	1		
Erythrocytes (Low) n=60, 61	0	1		
Platelets (Low) n=60, 61	4	0		

Platelets (High) n=189	0	1		
Leukocytes (Low) n=60, 61	1	1		
Leukocytes (High) n=60, 61	1	2		
Absolute Neutrophils + Bands (Low) n=60, 62	0	1		
Absolute Lymphocytes (Low) n=60, 62	2	3		
Absolute Eosinophils (High) n=60, 62	6	4		
Aspartate Aminotransferase (AST, High) n=60, 62	1	0		
Alanine Aminotransferase (ALT, High) n=60, 62	1	0		
Blood Urea Nitrogen (High) n=60, 62	1	1		
Serum Sodium (Low) n=60, 62	0	1		
Serum Potassium (High) n=60, 62	2	0		
Serum Glucose (Low) n=60, 62	4	5		
Serum Glucose (High) n=60, 62	0	1		
Fasting Serum Glucose (High) n=60, 62	1	1		
Urine Protein (High) n=62	2	2		
Urine Blood (High) n=60, 62	12	6		
Urine White Blood Cells (High) n=24, 20	5	2		
Urine Red Blood Cells (High) n=24, 20	6	4		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Treated Participants with Marked Laboratory Abnormalities During Open-Label Phase (Period C)

End point title	Number of Treated Participants with Marked Laboratory Abnormalities During Open-Label Phase (Period C)
End point description:	
<p>Marked abnormalities were pre-defined as changes after drug infusion relative to normal. Hemoglobin, 11.6-14.8 g/dL; Hematocrit, 36.0-50.0 percent; Erythrocytes, <math>3.80-5.10 \times 10^6</math> c/uL; Platelets, 140-44 c/L; Leukocytes, 4.00-12.50 c/uL; Absolute (Abs) Neutrophils + Bands, <math>&lt;1.00 \times 10^3</math> c/uL; Abs Lymphocytes, <math>&lt;0.72 \times 10^3</math> or <math>&gt;7.50 \times 10^3</math> c/uL; Abs Eosinophils, <math>&gt;0.750 \times 10^3</math> c/uL; Alkaline Phosphatase, 0-40 U/L; Aspartate Aminotransferase, 0-40 U/L; Alanine Aminotransferase, 0-40 U/L; G-Glutamyl Transferase, 0-60 U/L; Bilirubin, 0.1-1.2 mg/dL; Blood Urea Nitrogen, 5.9-26.0 mg/dL; Creatinine, 0.50-1.50 mg/dL; Inorganic Phosphorus, 2.8-6.2 U/L; Serum Potassium, 3.5-5.5 mEq/L; Serum Glucose, 65-99 mg/dL; Fasting Serum Glucose, 65-99 mg/dL; Total Protein, 6.0-8.5 g/dL; Albumin, 3.5-5.5 g/dL; Urine Protein, <math>\geq 4</math>; Urine Glucose, <math>\geq 4</math>; Urine Blood, <math>\geq 4</math>; Urine Red Blood Cells <math>\geq 4</math>; Urine White Blood Cells, <math>\geq 4</math>. The analysis population included all treated and evaluated subjects in Period C.</p>	
End point type	Secondary
End point timeframe:	
Period C (Day 282 to end of study)	

End point values	Abatacept (All Participants in Period C)			
Subject group type	Subject analysis set			
Number of subjects analysed	153			
Units: participants				
number (not applicable)				
Hemoglobin (Low) n=153	12			
Hematocrit (Low) n=153	8			
Erythrocytes (Low) n=153	4			
Platelet Count (Low) n=153	4			
Platelet Count (High) n=153	5			
Leukocytes (Low) n=153	20			
Leukocytes (High) n=153	18			
Absolute Neutrophils + Bands (Low)	14			
Absolute Lymphocytes (Low) n=153	21			
Absolute Lymphocytes (High) n=153	5			
Absolute Eosinophils (High) n=153	50			
Alkaline Phosphatase (ALP, High) n=153	2			
Aspartate Aminotransferase (AST, High)	5			
Alanine Aminotransferase (ALT, High) n=153	11			
G-Glutamyl Transferase (GGT, High) n=153	6			
Bilirubin (Total, High) n=153	3			
Blood Urea Nitrogen (High) n=153	15			
Creatinine (High) n=153	36			
Potassium (High) n=153	10			
Inorganic Phosphorus (High) n=153	4			
Serum Glucose (Low) n=153	54			
Serum Glucose (High) n=153	1			
Fasting Serum Glucose (Low) n=100	11			
Fasting Serum Glucose (High) n=100	7			
Total Protein (Low) n=153	1			
Total Protein (High) n=153	1			
Albumin (Low) n=153	9			
Urine Protein (High) n=153	35			
Urine Glucose (High) n=153	1			
Urine Blood (High) n=153	73			
Urine White Blood Cells (High) n=117	49			
Urine Red Blood Cells (High) n=117	86			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Participants With Anti-Abatacept or Anti-CTLA4 Positive Responses Over Time During Open-Label Phase (Period C)

End point title	Number of Participants With Anti-Abatacept or Anti-CTLA4 Positive Responses Over Time During Open-Label Phase (Period C)
-----------------	--



---

**End point description:**

During Period C, blood samples for immunogenicity assessments were obtained just prior to the start of the IV infusion of abatacept at 3-month intervals during the first 2 years of Period C, at 6-month intervals thereafter, and again 28, 56, and 85 days after the last infusion. Direct-format, enzyme-linked immunosorbent assays (ELISAs) were used to evaluate the cytotoxic T-lymphocyte antigen 4 (CTLA4) and the anti-CTLA4-T antibody.

The analysis population included all treated subjects who were evaluated for immunogenicity during Period C.

---

End point type	Secondary
----------------	-----------

---

**End point timeframe:**

Period C (Day 282 to 85 days after the last dose of study medication)

---

<b>End point values</b>	Abatacept (Period C)	Placebo (Period B) to Abatacept (Period C)	Abatacept (Period A Non-Responders in Period C)	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	57	58	33	
Units: participants				
number (not applicable)				
Anti-Abatacept, Overall on Treatment (n=31,54,54)	5	2	1	
Anti-Abatacept, Post-Treatment (n=25,41,38)	3	3	0	
Anti-CTLA4-T, Overall on Treatment (n=33,57,58)	4	4	4	
Anti-CTLA4-T, Overall Post-Treatment (n=27,46,42)	1	1	4	

---

**Statistical analyses**

No statistical analyses for this end point

---

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From first dose to last dose plus 56 days up to end of study (November 2011)

Adverse event reporting additional description:

Study initiated: February 2004; Study completed: November 2011

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	14.1
--------------------	------

### Reporting groups

Reporting group title	Abatacept (Only Period A)
-----------------------	---------------------------

Reporting group description:

Participants treated in Period A but did not in Periods B or C.

Abatacept: 10 milligram per kilogram body weight (mg/kg), limited to a maximum 1000 mg for participants weighing >100kg; solution infused intravenously (IV), over 90 minutes, once every 2 weeks for 3 doses.

Reporting group title	Abatacept (Period A/Period C)
-----------------------	-------------------------------

Reporting group description:

Participants treated in Period A, not eligible to continue into Period B, but re-entered in Period C.

Abatacept: 10 milligram per kilogram body weight (mg/kg), limited to a maximum 1000 mg for participants weighing >100kg; solution infused intravenously (IV), over 90 minutes, once every two weeks for three doses (Period A) and once a month for up to 5 years (Period C).

Reporting group title	Abatacept (Period A/Period B)
-----------------------	-------------------------------

Reporting group description:

All participants treated with Abatacept in Periods A and B who may or may not have entered Period C.

Abatacept: 10 milligram per kilogram body weight (mg/kg), limited to a maximum 1000 mg for participants weighing >100kg; solution infused intravenously (IV), over 90 minutes, once every 2 weeks for 3 doses, then once a month for 6 months. If participants entered Period C, treatment continued once a month for up to 5 years.

Reporting group title	Abatacept (Period A)/Placebo (Period B)
-----------------------	---

Reporting group description:

All participants treated with Abatacept in Period A, placebo in Period B, who may or may not have entered Period C.

Placebo: Dextrose 5% in water (D5W) or normal saline (NS) IV infusion, once every 2 weeks for 3 doses, then monthly up to 6 months. Participants were seated or in supine position during infusion. If participants entered Period C, they were treated with Abatacept, 10 milligram per kilogram body weight (mg/kg), limited to a maximum 1000 mg for participants weighing >100kg; solution infused intravenously (IV), over 90 minutes, once a month for up to 5 years.

Serious adverse events	Abatacept (Only Period A)	Abatacept (Period A/Period C)	Abatacept (Period A/Period B)
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 32 (12.50%)	10 / 36 (27.78%)	9 / 60 (15.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0		

Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Fibroadenoma of breast			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	0 / 36 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute lymphocytic leukaemia			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 32 (3.13%)	0 / 36 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Haematoma			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	0 / 36 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Fatigue			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	0 / 36 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Condition aggravated			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	1 / 36 (2.78%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	0 / 36 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Immune system disorders			
Food allergy			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	0 / 36 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypersensitivity			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	0 / 36 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Ovarian cyst			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 32 (3.13%)	0 / 36 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Suicide attempt			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	0 / 36 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Joint dislocation			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	0 / 36 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Overdose			
alternative dictionary used: MedDRA 14.1			

subjects affected / exposed	0 / 32 (0.00%)	0 / 36 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple injuries			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	0 / 36 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Encephalitis			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	0 / 36 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Temporal lobe epilepsy			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	0 / 36 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple sclerosis			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	0 / 36 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	0 / 36 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
alternative dictionary used: MedDRA 14.1			

subjects affected / exposed	0 / 32 (0.00%)	0 / 36 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	0 / 36 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Skin ulcer			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	1 / 36 (2.78%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthritis			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	3 / 36 (8.33%)	3 / 60 (5.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot deformity			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	0 / 36 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rheumatoid arthritis			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	2 / 32 (6.25%)	1 / 36 (2.78%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Torticollis			
alternative dictionary used: MedDRA 14.1			

subjects affected / exposed	0 / 32 (0.00%)	1 / 36 (2.78%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthralgia			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	1 / 36 (2.78%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthropathy			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	0 / 36 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Juvenile arthritis			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	1 / 36 (2.78%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Synovial cyst			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	0 / 36 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Erysipelas			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	0 / 36 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abscess limb			
alternative dictionary used: MedDRA 14.1			

subjects affected / exposed	0 / 32 (0.00%)	1 / 36 (2.78%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	0 / 36 (0.00%)	2 / 60 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	0 / 36 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	1 / 36 (2.78%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis bacterial			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	1 / 36 (2.78%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tooth abscess			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	0 / 36 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis bacterial			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	1 / 36 (2.78%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0



Dengue fever alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all			
	0 / 32 (0.00%)	1 / 36 (2.78%)	0 / 60 (0.00%)
	0 / 0	0 / 1	0 / 0
	0 / 0	0 / 0	0 / 0
Pyelonephritis alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all			
	0 / 32 (0.00%)	1 / 36 (2.78%)	1 / 60 (1.67%)
	0 / 0	0 / 1	0 / 1
	0 / 0	0 / 0	0 / 0
Varicella alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all			
	0 / 32 (0.00%)	1 / 36 (2.78%)	0 / 60 (0.00%)
	0 / 0	0 / 1	0 / 0
	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders Type 1 diabetes mellitus alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all			
	0 / 32 (0.00%)	0 / 36 (0.00%)	1 / 60 (1.67%)
	0 / 0	0 / 0	0 / 1
	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Abatacept (Period A)/Placebo (Period		
Total subjects affected by serious adverse events subjects affected / exposed number of deaths (all causes) number of deaths resulting from adverse events	14 / 62 (22.58%) 0 0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Fibroadenoma of breast alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 62 (0.00%) 0 / 0 0 / 0		
Acute lymphocytic leukaemia			

alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Haematoma			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Fatigue			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Condition aggravated			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pyrexia			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
Food allergy			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hypersensitivity			

alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Reproductive system and breast disorders			
Ovarian cyst			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Suicide attempt			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Joint dislocation			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Overdose			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Multiple injuries			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			

Encephalitis alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 62 (1.61%) 0 / 1 0 / 0		
Temporal lobe epilepsy alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 62 (1.61%) 0 / 1 0 / 0		
Multiple sclerosis alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 62 (1.61%) 0 / 1 0 / 0		
Gastrointestinal disorders Abdominal pain alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 62 (0.00%) 0 / 0 0 / 0		
Vomiting alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 62 (1.61%) 0 / 1 0 / 0		
Nausea alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 62 (1.61%) 0 / 1 0 / 0		
Skin and subcutaneous tissue disorders Skin ulcer alternative dictionary used: MedDRA 14.1			

subjects affected / exposed	0 / 62 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Arthritis			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Foot deformity			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Rheumatoid arthritis			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Torticollis			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Arthralgia			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Arthropathy			
alternative dictionary used: MedDRA 14.1			

subjects affected / exposed	1 / 62 (1.61%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Juvenile arthritis				
alternative dictionary used: MedDRA 14.1				
subjects affected / exposed	0 / 62 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Synovial cyst				
alternative dictionary used: MedDRA 14.1				
subjects affected / exposed	1 / 62 (1.61%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Infections and infestations				
Erysipelas				
alternative dictionary used: MedDRA 14.1				
subjects affected / exposed	1 / 62 (1.61%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Abscess limb				
alternative dictionary used: MedDRA 14.1				
subjects affected / exposed	0 / 62 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Appendicitis				
alternative dictionary used: MedDRA 14.1				
subjects affected / exposed	0 / 62 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis				
alternative dictionary used: MedDRA 14.1				

subjects affected / exposed	1 / 62 (1.61%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Herpes zoster				
alternative dictionary used: MedDRA 14.1				
subjects affected / exposed	0 / 62 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Meningitis bacterial				
alternative dictionary used: MedDRA 14.1				
subjects affected / exposed	0 / 62 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Tooth abscess				
alternative dictionary used: MedDRA 14.1				
subjects affected / exposed	0 / 62 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Arthritis bacterial				
alternative dictionary used: MedDRA 14.1				
subjects affected / exposed	1 / 62 (1.61%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Dengue fever				
alternative dictionary used: MedDRA 14.1				
subjects affected / exposed	0 / 62 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pyelonephritis				
alternative dictionary used: MedDRA 14.1				
subjects affected / exposed	0 / 62 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

Varicella alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 62 (1.61%) 0 / 1 0 / 0		
Metabolism and nutrition disorders Type 1 diabetes mellitus alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 62 (0.00%) 0 / 0 0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Abatacept (Only Period A)	Abatacept (Period A/Period C)	Abatacept (Period A/Period B)
Total subjects affected by non-serious adverse events subjects affected / exposed	22 / 32 (68.75%)	32 / 36 (88.89%)	57 / 60 (95.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Skin papilloma alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)	1 / 32 (3.13%) 1	0 / 36 (0.00%) 0	3 / 60 (5.00%) 3
Vascular disorders Hypertension alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)  Flushing alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0  2 / 32 (6.25%) 2	2 / 36 (5.56%) 2  0 / 36 (0.00%) 0	2 / 60 (3.33%) 2  0 / 60 (0.00%) 0
General disorders and administration site conditions Fatigue alternative dictionary used: MedDRA 14.1			



subjects affected / exposed	2 / 32 (6.25%)	2 / 36 (5.56%)	0 / 60 (0.00%)
occurrences (all)	2	2	0
Chest pain			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	2 / 36 (5.56%)	2 / 60 (3.33%)
occurrences (all)	0	2	2
Pain			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 32 (3.13%)	2 / 36 (5.56%)	0 / 60 (0.00%)
occurrences (all)	1	2	0
Chills			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	0 / 36 (0.00%)	3 / 60 (5.00%)
occurrences (all)	0	0	3
Influenza like illness			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	0 / 36 (0.00%)	3 / 60 (5.00%)
occurrences (all)	0	0	3
Pyrexia			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	2 / 32 (6.25%)	8 / 36 (22.22%)	12 / 60 (20.00%)
occurrences (all)	4	12	17
Reproductive system and breast disorders			
Vaginal discharge			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	2 / 36 (5.56%)	1 / 60 (1.67%)
occurrences (all)	0	2	1
Respiratory, thoracic and mediastinal disorders			
Oropharyngeal pain			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	4 / 32 (12.50%)	3 / 36 (8.33%)	8 / 60 (13.33%)
occurrences (all)	6	3	10
Rhinitis allergic			
alternative dictionary used: MedDRA 14.1			

subjects affected / exposed	2 / 32 (6.25%)	1 / 36 (2.78%)	4 / 60 (6.67%)
occurrences (all)	2	1	4
Cough			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	4 / 32 (12.50%)	7 / 36 (19.44%)	10 / 60 (16.67%)
occurrences (all)	6	10	13
Epistaxis			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	2 / 32 (6.25%)	2 / 36 (5.56%)	0 / 60 (0.00%)
occurrences (all)	2	2	0
Nasal congestion			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	2 / 32 (6.25%)	0 / 36 (0.00%)	1 / 60 (1.67%)
occurrences (all)	2	0	1
Dyspnoea			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	2 / 36 (5.56%)	0 / 60 (0.00%)
occurrences (all)	0	2	0
Rhinorrhoea			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	2 / 36 (5.56%)	3 / 60 (5.00%)
occurrences (all)	0	2	3
Psychiatric disorders			
Insomnia			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	2 / 32 (6.25%)	0 / 36 (0.00%)	0 / 60 (0.00%)
occurrences (all)	2	0	0
Investigations			
Alanine aminotransferase increased			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	0 / 36 (0.00%)	5 / 60 (8.33%)
occurrences (all)	0	0	6
Transaminases increased			
alternative dictionary used: MedDRA 14.1			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Aspartate aminotransferase increased</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 32 (0.00%)</p> <p>0</p> <p>0 / 32 (0.00%)</p> <p>0</p>	<p>1 / 36 (2.78%)</p> <p>1</p> <p>0 / 36 (0.00%)</p> <p>0</p>	<p>3 / 60 (5.00%)</p> <p>3</p> <p>3 / 60 (5.00%)</p> <p>3</p>
<p>Injury, poisoning and procedural complications</p> <p>Joint injury</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Arthropod bite</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Fall</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 32 (0.00%)</p> <p>0</p> <p>0 / 32 (0.00%)</p> <p>0</p> <p>0 / 32 (0.00%)</p> <p>0</p>	<p>1 / 36 (2.78%)</p> <p>1</p> <p>2 / 36 (5.56%)</p> <p>2</p> <p>0 / 36 (0.00%)</p> <p>0</p>	<p>1 / 60 (1.67%)</p> <p>1</p> <p>0 / 60 (0.00%)</p> <p>0</p> <p>2 / 60 (3.33%)</p> <p>2</p>
<p>Nervous system disorders</p> <p>Dizziness</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Headache</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>4 / 32 (12.50%)</p> <p>6</p> <p>7 / 32 (21.88%)</p> <p>10</p>	<p>3 / 36 (8.33%)</p> <p>4</p> <p>10 / 36 (27.78%)</p> <p>14</p>	<p>7 / 60 (11.67%)</p> <p>10</p> <p>14 / 60 (23.33%)</p> <p>20</p>
<p>Blood and lymphatic system disorders</p> <p>Anaemia</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Leukopenia</p> <p>alternative dictionary used:</p>	<p>0 / 32 (0.00%)</p> <p>0</p>	<p>2 / 36 (5.56%)</p> <p>2</p>	<p>3 / 60 (5.00%)</p> <p>3</p>

MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	3 / 36 (8.33%)	4 / 60 (6.67%)
occurrences (all)	0	3	4
Eosinophilia			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	4 / 36 (11.11%)	5 / 60 (8.33%)
occurrences (all)	0	6	8
Ear and labyrinth disorders			
Ear pain			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	0 / 36 (0.00%)	1 / 60 (1.67%)
occurrences (all)	0	0	1
Eye disorders			
Cataract			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	2 / 36 (5.56%)	1 / 60 (1.67%)
occurrences (all)	0	2	1
Conjunctivitis allergic			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	0 / 36 (0.00%)	4 / 60 (6.67%)
occurrences (all)	0	0	4
Conjunctivitis			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	4 / 36 (11.11%)	5 / 60 (8.33%)
occurrences (all)	0	4	5
Gastrointestinal disorders			
Diarrhoea			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	2 / 32 (6.25%)	8 / 36 (22.22%)	11 / 60 (18.33%)
occurrences (all)	2	11	14
Mouth ulceration			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	2 / 32 (6.25%)	1 / 36 (2.78%)	3 / 60 (5.00%)
occurrences (all)	2	1	4
Abdominal discomfort			
alternative dictionary used:			

MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	2 / 36 (5.56%)	2 / 60 (3.33%)
occurrences (all)	0	4	5
Abdominal pain			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 32 (3.13%)	6 / 36 (16.67%)	8 / 60 (13.33%)
occurrences (all)	1	6	8
Abdominal pain upper			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	5 / 36 (13.89%)	10 / 60 (16.67%)
occurrences (all)	0	5	10
Duodenitis			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	2 / 36 (5.56%)	0 / 60 (0.00%)
occurrences (all)	0	2	0
Gastritis			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	6 / 36 (16.67%)	6 / 60 (10.00%)
occurrences (all)	0	6	6
Vomiting			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	2 / 32 (6.25%)	7 / 36 (19.44%)	9 / 60 (15.00%)
occurrences (all)	4	8	11
Aphthous stomatitis			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 32 (3.13%)	3 / 36 (8.33%)	3 / 60 (5.00%)
occurrences (all)	1	3	3
Dyspepsia			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	1 / 36 (2.78%)	4 / 60 (6.67%)
occurrences (all)	0	1	4
Nausea			
alternative dictionary used: MedDRA 14.1			

subjects affected / exposed occurrences (all)	6 / 32 (18.75%) 6	5 / 36 (13.89%) 5	9 / 60 (15.00%) 12
Skin and subcutaneous tissue disorders			
Pruritus alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)	1 / 32 (3.13%) 1	2 / 36 (5.56%) 2	2 / 60 (3.33%) 2
Eczema alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2	0 / 36 (0.00%) 0	2 / 60 (3.33%) 2
Rash alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	1 / 36 (2.78%) 1	3 / 60 (5.00%) 3
Dermatitis alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	1 / 36 (2.78%) 1	3 / 60 (5.00%) 3
Renal and urinary disorders			
Haematuria alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	2 / 36 (5.56%) 2	5 / 60 (8.33%) 6
Dysuria alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 36 (0.00%) 0	4 / 60 (6.67%) 4
Leukocyturia alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	2 / 36 (5.56%) 2	1 / 60 (1.67%) 1
Musculoskeletal and connective tissue disorders			

<p>Myalgia</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 32 (0.00%)</p> <p>0</p>	<p>0 / 36 (0.00%)</p> <p>0</p>	<p>3 / 60 (5.00%)</p> <p>4</p>
<p>Torticollis</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 32 (0.00%)</p> <p>0</p>	<p>2 / 36 (5.56%)</p> <p>2</p>	<p>1 / 60 (1.67%)</p> <p>2</p>
<p>Arthralgia</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 32 (0.00%)</p> <p>0</p>	<p>1 / 36 (2.78%)</p> <p>1</p>	<p>1 / 60 (1.67%)</p> <p>1</p>
<p>Back pain</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 32 (0.00%)</p> <p>0</p>	<p>3 / 36 (8.33%)</p> <p>3</p>	<p>5 / 60 (8.33%)</p> <p>5</p>
<p>Infections and infestations</p> <p>Pneumonia</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 32 (0.00%)</p> <p>0</p>	<p>2 / 36 (5.56%)</p> <p>2</p>	<p>0 / 60 (0.00%)</p> <p>0</p>
<p>Bacteriuria</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 32 (0.00%)</p> <p>0</p>	<p>2 / 36 (5.56%)</p> <p>2</p>	<p>6 / 60 (10.00%)</p> <p>8</p>
<p>Pharyngitis streptococcal</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 32 (6.25%)</p> <p>2</p>	<p>0 / 36 (0.00%)</p> <p>0</p>	<p>0 / 60 (0.00%)</p> <p>1</p>
<p>Pharyngotonsillitis</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 32 (0.00%)</p> <p>0</p>	<p>2 / 36 (5.56%)</p> <p>2</p>	<p>3 / 60 (5.00%)</p> <p>3</p>
<p>Vulvovaginitis</p> <p>alternative dictionary used: MedDRA 14.1</p>			

subjects affected / exposed	0 / 32 (0.00%)	4 / 36 (11.11%)	1 / 60 (1.67%)
occurrences (all)	0	4	1
Fungal skin infection			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	3 / 36 (8.33%)	3 / 60 (5.00%)
occurrences (all)	0	3	3
Impetigo			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	3 / 36 (8.33%)	2 / 60 (3.33%)
occurrences (all)	0	3	2
Pneumonia primary atypical			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	2 / 36 (5.56%)	0 / 60 (0.00%)
occurrences (all)	0	2	0
Rhinitis			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	6 / 36 (16.67%)	8 / 60 (13.33%)
occurrences (all)	0	8	8
Gastroenteritis			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 32 (3.13%)	4 / 36 (11.11%)	6 / 60 (10.00%)
occurrences (all)	1	5	8
Tonsillitis			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	6 / 36 (16.67%)	7 / 60 (11.67%)
occurrences (all)	0	8	10
Upper respiratory tract infection			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	3 / 32 (9.38%)	12 / 36 (33.33%)	11 / 60 (18.33%)
occurrences (all)	3	12	11
Urinary tract infection			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	2 / 36 (5.56%)	10 / 60 (16.67%)
occurrences (all)	0	2	10



Lice infestation			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	2 / 36 (5.56%)	3 / 60 (5.00%)
occurrences (all)	0	2	3
Pharyngitis			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	3 / 36 (8.33%)	10 / 60 (16.67%)
occurrences (all)	0	3	12
Nasopharyngitis			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	3 / 32 (9.38%)	11 / 36 (30.56%)	20 / 60 (33.33%)
occurrences (all)	3	14	15
Sinusitis			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 32 (3.13%)	5 / 36 (13.89%)	12 / 60 (20.00%)
occurrences (all)	1	5	15
Paronychia			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	2 / 32 (6.25%)	3 / 36 (8.33%)	3 / 60 (5.00%)
occurrences (all)	2	3	3
Tinea versicolour			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	1 / 36 (2.78%)	3 / 60 (5.00%)
occurrences (all)	0	1	3
Varicella			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	1 / 36 (2.78%)	3 / 60 (5.00%)
occurrences (all)	0	1	3
Viral infection			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	3 / 32 (9.38%)	0 / 36 (0.00%)	2 / 60 (3.33%)
occurrences (all)	0	3	2
Bronchitis			
alternative dictionary used: MedDRA 14.1			

subjects affected / exposed	0 / 32 (0.00%)	2 / 36 (5.56%)	8 / 60 (13.33%)
occurrences (all)	0	2	10
Influenza			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 32 (3.13%)	6 / 36 (16.67%)	16 / 60 (26.67%)
occurrences (all)	1	8	20
Otitis media acute			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	2 / 36 (5.56%)	1 / 60 (1.67%)
occurrences (all)	0	2	1
Metabolism and nutrition disorders			
Decreased appetite			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 32 (0.00%)	2 / 36 (5.56%)	3 / 60 (5.00%)
occurrences (all)	0	2	3

<b>Non-serious adverse events</b>	Abatacept (Period A)/Placebo (Period		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	54 / 62 (87.10%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Skin papilloma			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	4 / 62 (6.45%)		
occurrences (all)	4		
Vascular disorders			
Hypertension			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Flushing			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
General disorders and administration site conditions			

<p>Fatigue</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 62 (1.61%)</p> <p>2</p>		
<p>Chest pain</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 62 (3.23%)</p> <p>2</p>		
<p>Pain</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 62 (3.23%)</p> <p>2</p>		
<p>Chills</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 62 (1.61%)</p> <p>1</p>		
<p>Influenza like illness</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>4 / 62 (6.45%)</p> <p>4</p>		
<p>Pyrexia</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>12 / 62 (19.35%)</p> <p>15</p>		
<p>Reproductive system and breast disorders</p> <p>Vaginal discharge</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 62 (1.61%)</p> <p>1</p>		
<p>Respiratory, thoracic and mediastinal disorders</p> <p>Oropharyngeal pain</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>8 / 62 (12.90%)</p> <p>8</p>		

<p>Rhinitis allergic</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 62 (3.23%)</p> <p>2</p>		
<p>Cough</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>13 / 62 (20.97%)</p> <p>17</p>		
<p>Epistaxis</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 62 (0.00%)</p> <p>0</p>		
<p>Nasal congestion</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 62 (1.61%)</p> <p>1</p>		
<p>Dyspnoea</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 62 (0.00%)</p> <p>0</p>		
<p>Rhinorrhoea</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 62 (3.23%)</p> <p>2</p>		
<p>Psychiatric disorders</p> <p>Insomnia</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 62 (1.61%)</p> <p>1</p>		
<p>Investigations</p> <p>Alanine aminotransferase increased</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Transaminases increased</p>	<p>2 / 62 (3.23%)</p> <p>4</p>		

<p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 62 (1.61%)</p> <p>1</p>		
<p>Aspartate aminotransferase increased</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 62 (3.23%)</p> <p>2</p>		
<p>Injury, poisoning and procedural complications</p> <p>Joint injury</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Arthropod bite</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Fall</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>5 / 62 (8.06%)</p> <p>5</p> <p>2 / 62 (3.23%)</p> <p>2</p> <p>5 / 62 (8.06%)</p> <p>6</p>		
<p>Nervous system disorders</p> <p>Dizziness</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Headache</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>4 / 62 (6.45%)</p> <p>6</p> <p>11 / 62 (17.74%)</p> <p>14</p>		
<p>Blood and lymphatic system disorders</p> <p>Anaemia</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>5 / 62 (8.06%)</p> <p>5</p>		

<p>Leukopenia</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>3 / 62 (4.84%)</p> <p>3</p>		
<p>Eosinophilia</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>6 / 62 (9.68%)</p> <p>6</p>		
<p>Ear and labyrinth disorders</p> <p>Ear pain</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>4 / 62 (6.45%)</p> <p>4</p>		
<p>Eye disorders</p> <p>Cataract</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Conjunctivitis allergic</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Conjunctivitis</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 62 (0.00%)</p> <p>0</p> <p>0 / 62 (0.00%)</p> <p>0</p> <p>4 / 62 (6.45%)</p> <p>4</p>		
<p>Gastrointestinal disorders</p> <p>Diarrhoea</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Mouth ulceration</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Abdominal discomfort</p>	<p>15 / 62 (24.19%)</p> <p>18</p> <p>4 / 62 (6.45%)</p> <p>4</p>		

alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Abdominal pain			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	8 / 62 (12.90%)		
occurrences (all)	8		
Abdominal pain upper			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	10 / 62 (16.13%)		
occurrences (all)	10		
Duodenitis			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Gastritis			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	5 / 62 (8.06%)		
occurrences (all)	5		
Vomiting			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	13 / 62 (20.97%)		
occurrences (all)	15		
Aphthous stomatitis			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	2 / 62 (3.23%)		
occurrences (all)	3		
Dyspepsia			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	3 / 62 (4.84%)		
occurrences (all)	3		
Nausea			
alternative dictionary used: MedDRA 14.1			

subjects affected / exposed occurrences (all)	12 / 62 (19.35%) 15		
Skin and subcutaneous tissue disorders			
Pruritus alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)	1 / 62 (1.61%) 1		
Eczema alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)	4 / 62 (6.45%) 4		
Rash alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)	5 / 62 (8.06%) 5		
Dermatitis alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Renal and urinary disorders			
Haematuria alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)	4 / 62 (6.45%) 4		
Dysuria alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)	4 / 62 (6.45%) 4		
Leukocyturia alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Musculoskeletal and connective tissue disorders			



<p>Myalgia</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>4 / 62 (6.45%)</p> <p>5</p>		
<p>Torticollis</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 62 (0.00%)</p> <p>0</p>		
<p>Arthralgia</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>4 / 62 (6.45%)</p> <p>4</p>		
<p>Back pain</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 62 (3.23%)</p> <p>2</p>		
<p>Infections and infestations</p> <p>Pneumonia</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Bacteriuria</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Pharyngitis streptococcal</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Pharyngotonsillitis</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Vulvovaginitis</p> <p>alternative dictionary used: MedDRA 14.1</p>	<p>0 / 62 (0.00%)</p> <p>0</p> <p>2 / 62 (3.23%)</p> <p>2</p> <p>1 / 62 (1.61%)</p> <p>1</p> <p>1 / 62 (1.61%)</p> <p>1</p>		

subjects affected / exposed	2 / 62 (3.23%)		
occurrences (all)	2		
Fungal skin infection			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	2 / 62 (3.23%)		
occurrences (all)	2		
Impetigo			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	2 / 62 (3.23%)		
occurrences (all)	2		
Pneumonia primary atypical			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Rhinitis			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	9 / 62 (14.52%)		
occurrences (all)	12		
Gastroenteritis			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	5 / 62 (8.06%)		
occurrences (all)	5		
Tonsillitis			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	3 / 62 (4.84%)		
occurrences (all)	3		
Upper respiratory tract infection			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	12 / 62 (19.35%)		
occurrences (all)	12		
Urinary tract infection			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	3 / 62 (4.84%)		
occurrences (all)	3		

Lice infestation			
alternative dictionary used:			
MedDRA 14.1			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Pharyngitis			
alternative dictionary used:			
MedDRA 14.1			
subjects affected / exposed	13 / 62 (20.97%)		
occurrences (all)	15		
Nasopharyngitis			
alternative dictionary used:			
MedDRA 14.1			
subjects affected / exposed	15 / 62 (24.19%)		
occurrences (all)	20		
Sinusitis			
alternative dictionary used:			
MedDRA 14.1			
subjects affected / exposed	7 / 62 (11.29%)		
occurrences (all)	7		
Paronychia			
alternative dictionary used:			
MedDRA 14.1			
subjects affected / exposed	2 / 62 (3.23%)		
occurrences (all)	2		
Tinea versicolour			
alternative dictionary used:			
MedDRA 14.1			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Varicella			
alternative dictionary used:			
MedDRA 14.1			
subjects affected / exposed	3 / 62 (4.84%)		
occurrences (all)	3		
Viral infection			
alternative dictionary used:			
MedDRA 14.1			
subjects affected / exposed	4 / 62 (6.45%)		
occurrences (all)	4		
Bronchitis			
alternative dictionary used:			
MedDRA 14.1			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Influenza</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Otitis media acute</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>4 / 62 (6.45%)</p> <p>4</p> <p>12 / 62 (19.35%)</p> <p>12</p> <p>3 / 62 (4.84%)</p> <p>3</p>		
<p>Metabolism and nutrition disorders</p> <p>Decreased appetite</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 62 (0.00%)</p> <p>0</p>		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
01 December 2003	Clarified that Period C would continue for 2 years or until abatacept is approved for the indication of JRA/JIA in each local country.
08 November 2006	Decreased frequency of efficacy, safety and laboratory assessments beginning with study Day C701 to once every 6 months; removed requirement for male contraception use; stated that use of abatacept in combination with another biologic agent for RA was not recommended; minor editorial clarifications.
26 April 2010	Implemented collection of biomarkers typically associated with diabetes and hypothyroidism to examine the potential relationship between abatacept treatment and the development of immunogenicity in influencing the onset of autoimmune disorders.
30 September 2010	Terminated the study by December 2011 based on the fact that abatacept was commercially available to treat JRA in the IM101033 participating countries.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported